Sandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading position in cephalosporinsAcquisition confirms Sandoz co…
Entries by https://www.sandoz.com/rss/feeds/news/media-releases.xml
Company previously disclosed settlement agreement in principle and fully provisioned for this resolutionBasel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement agreement with the Civil Division of the U.S. Departme…
Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further e…
Ad hoc announcement pursuant to Art. 53 LRNet sales in Q2 grew +9% (cc¹, +14% USD):Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21% cc) and Zolgensma (+48% cc). Kesimpta sales reached USD …
Patients with iron deficiency anemia in a hospital or clinic setting now have access to an important IV iron medicine at a more affordable priceIron deficiency anemia occurs when there is a lower than normal number of oxygen-carrying red blood cells be…
Pemetrexed is indicated for patients with non-squamous Non-Small Cell Lung Cancer (NSCLC), who represent over 3 in 4 patients with lung cancer1New ready-to-dilute format and 1,000 mg strength option helps avoid unnecessary handling steps to reduce asso…
Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls,…
Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by chronic autoimmune and inflammatory disease have to wai…
Sandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study1Neovascular age-related macular degeneration accounts for 10% of age-related macular degeneration cases, bu…
Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.
Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 billion)Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with continued strong growth from Entresto (+34% cc), Zolgensma (…